Maravai LifeSciences Acquires MyChem
January 28, 2022
Maravai LifeSciences (NASDAQ: MRVI) acquired MyChem, LLC, a San Diego-based provider of ultra-pure nucleotides, for $240 million in cash plus potential contingent consideration. The acquisition integrates MyChem into Maravai's TriLink nucleic acid production business to expand capabilities for mRNA synthesis, accelerate R&D and support GMP manufacturing for vaccine, therapeutic and diagnostic customers.
- Buyers
- Maravai LifeSciences, Inc.
- Targets
- MyChem, LLC
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Thompson Street Capital Partners Acquires Vector Laboratories (Maravai Protein Detection Business)
September 7, 2021
Biotechnology
Thompson Street Capital Partners (TSCP), a St. Louis-based private equity firm, has acquired Vector Laboratories, the Protein Detection business unit of Maravai (NASDAQ: MRVI). Vector Laboratories is a manufacturer of labeling and visual detection reagents used in tissue-based protein detection for academic and corporate research; TSCP said the deal expands its life sciences capabilities and positions Vector for organic and strategic growth.
-
Verdesian Life Sciences Acquires Cytozyme Laboratories
April 27, 2021
Agriculture
Verdesian Life Sciences has acquired Cytozyme Laboratories, Inc.; Cascadia Capital served as exclusive financial advisor to Cytozyme. The acquisition brings together complementary biological and nutritional crop technologies to expand Verdesian's product portfolio and support sustainable yield solutions for growers.
-
BioMatrix Infusion Pharmacy Acquires MyLyfe Health
March 3, 2025
Healthcare Services
BioMatrix Infusion Pharmacy, a nationwide specialty infusion pharmacy based in Plantation, Florida, has acquired MyLyfe Health, a New England–based specialty pharmacy and home infusion services provider. The acquisition expands BioMatrix's geographic footprint into New England and enhances its ambulatory and home infusion capabilities to better serve patients with chronic, lifelong conditions.
-
X-Chem Acquires IntelliSyn and AviSyn to Expand Drug Discovery Services
January 26, 2021
Biotechnology
X-Chem, a portfolio company of GHO Capital, has acquired Montreal-based IntelliSyn and its US-based sister company AviSyn to extend its drug discovery offering into medicinal chemistry, custom synthesis and scale-up process chemistry. The deal integrates downstream hit validation and lead optimisation capabilities into X-Chem’s DNA-Encoded Library (DEL) platform, enabling a streamlined screen-to-lead service for pharma and biotech clients; financial terms were not disclosed.
-
Millstone Medical Outsourcing Acquires MycoScience
November 14, 2022
Healthcare Services
Millstone Medical Outsourcing, an Arlington Capital Partners portfolio company, has completed the acquisition of MycoScience, a Willington, Connecticut-based provider of medical device and pharmaceutical laboratory and environmental testing services. The acquisition adds advanced laboratory and regulatory testing capabilities to Millstone's post-manufacturing and aftermarket services, enabling more in-house testing, faster time to market, and expanded end-to-end offerings.
-
Sygnature Discovery Acquires NuChem Sciences
August 1, 2023
Biotechnology
UK-based integrated drug discovery CRO Sygnature Discovery has acquired Montreal-headquartered NuChem Sciences, one of North America's largest discovery contract research organisations. The deal expands Sygnature's global footprint and capabilities in medicinal chemistry, DMPK, structural biology and in vitro/in vivo pharmacology, strengthening its position in the North American market.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.